LANTERN PHARMA INC (LTRN) Stock Price & Overview
NASDAQ:LTRN • US51654W1018
Current stock price
The current stock price of LTRN is 2.76 USD. Today LTRN is up by 10.84%. In the past month the price increased by 29.58%. In the past year, price decreased by -23.12%.
LTRN Key Statistics
- Market Cap
- 31.05M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.57
- Dividend Yield
- N/A
LTRN Stock Performance
LTRN Stock Chart
LTRN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LTRN. When comparing the yearly performance of all stocks, LTRN is a bad performer in the overall market: 87.31% of all stocks are doing better.
LTRN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LTRN. The financial health of LTRN is average, but there are quite some concerns on its profitability.
LTRN Earnings
LTRN Forecast & Estimates
7 analysts have analysed LTRN and the average price target is 25.5 USD. This implies a price increase of 823.91% is expected in the next year compared to the current price of 2.76.
LTRN Groups
Sector & Classification
LTRN Financial Highlights
Over the last trailing twelve months LTRN reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS increased by 18.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.85% | ||
| ROE | -197.36% | ||
| Debt/Equity | 0 |
LTRN Ownership
LTRN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LTRN
Company Profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Company Info
IPO: 2020-06-11
LANTERN PHARMA INC
1920 Mckinney Avenue, 7th Floor
Dallas TEXAS 75201 US
CEO: Panna Sharma
Employees: 24
Phone: 19722771136
LANTERN PHARMA INC / LTRN FAQ
Can you describe the business of LANTERN PHARMA INC?
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
What is the current price of LTRN stock?
The current stock price of LTRN is 2.76 USD. The price increased by 10.84% in the last trading session.
What is the dividend status of LANTERN PHARMA INC?
LTRN does not pay a dividend.
How is the ChartMill rating for LANTERN PHARMA INC?
LTRN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is LANTERN PHARMA INC worth?
LANTERN PHARMA INC (LTRN) has a market capitalization of 31.05M USD. This makes LTRN a Nano Cap stock.
Can you provide the ownership details for LTRN stock?
You can find the ownership structure of LANTERN PHARMA INC (LTRN) on the Ownership tab.
What is the Short Interest ratio of LANTERN PHARMA INC (LTRN) stock?
The outstanding short interest for LANTERN PHARMA INC (LTRN) is 22.46% of its float.